An all-purpose antimalarial drug target.
The recent re-emphasis on malaria eradication has made developing drugs that block transmission and terminate latent disease critical. Most drugs do not affect the liver stages-an ability that is crucial to the latter goal. Addressing this problem, Hoepfner et al. (2012) uncover the parasite's lysyl-tRNA synthetase as a druggable target.
Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA.
W Armand
WA
Guiguemde
R Kiplin
RK
Guy
D000962:Antimalarials / Q000494:pharmacology*; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005658:Fungi / Q000737:chemistry*; D006801:Humans; D049934:Isocoumarins / Q000494:pharmacology*; D008250:Lysine-tRNA Ligase / Q000037:antagonists & inhibitors*; D010963:Plasmodium falciparum / Q000201:enzymology*
D000962:Antimalarials; D004791:Enzyme Inhibitors; D049934:Isocoumarins; D008250:Lysine-tRNA Ligase